跳至主要内容
临床试验/NCT00135447
NCT00135447已完成不适用

A Phase IV, Multicenter, Cross-sectional Study to Evaluate the I50L Substitution Among Subjects Experiencing Virologic Failure on a HAART Regimen Containing Atazanavir (ATV)

Bristol-Myers Squibb81 个研究点 分布在 1 个国家目标入组 5,000 人开始时间: 2004年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
5,000
试验地点
81

研究概览

简要总结

The purpose of this study is to find out the frequency of the I50L substitution among patients experiencing treatment failure on an atazanavir-containing regimen.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Atazanavir - containing antiretroviral regimen
  • Confirmed virologic failure defined as either:
  • HIV RNA by PCR greater than or equal to 1000 copies/mL after achieving a value of <400 copies/mL on at least 2 consecutive measurements or
  • HIV RNA greater than or equal to 1000 copies/mL after 24 weeks of continuous therapy
  • At least 18 years old

排除标准

  • Unable to give informed consent
  • Prisoners or subjects involuntarily incarcerated for treatment of psychiatric or physical illness

研究者

发起方
Bristol-Myers Squibb
申办方类型
Industry

研究点 (81)

Loading locations...

相似试验